Drug Class: SGLT2 Inhibitor + DPP-4 Inhibitor Combination | Form: Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Xenglu-Lin 25/5mg Tablet?
Xenglu-Lin 25/5mg is a fixed-dose combination of two complementary diabetes medicines — Empagliflozin 25mg and Linagliptin 5mg — working through two completely different mechanisms to control blood sugar more effectively than either medicine alone. Empagliflozin removes excess glucose through the kidneys while Linagliptin stimulates the body's own insulin response in a glucose-dependent manner. This dual approach is prescribed when a single diabetes medicine no longer provides adequate blood sugar control, offering the convenience of two treatments in one tablet alongside meaningful cardiovascular and kidney-protective benefits.
What is Xenglu-Lin 25/5mg Used For?
- Type 2 diabetes mellitus — improving blood sugar control when single-agent therapy is insufficient (ذیابیطس)
- Dual-mechanism glycaemic management — combining kidney glucose excretion with enhanced insulin stimulation
- Cardiovascular risk reduction — Empagliflozin component reduces cardiovascular death risk in high-risk patients
- Simplification of diabetes regimen — replacing two separate tablets with a single convenient combination
How Does Xenglu-Lin 25/5mg Work?
Empagliflozin 25mg — SGLT2 Inhibitor: Blocks SGLT2 transporters in the kidney's proximal tubule, preventing glucose reabsorption back into the bloodstream. This causes approximately 70–90g of excess glucose to be excreted in urine daily — lowering blood sugar independently of insulin. It also produces modest reductions in body weight and blood pressure as additional benefits.
Linagliptin 5mg — DPP-4 Inhibitor: Blocks the DPP-4 enzyme that normally breaks down incretin hormones (GLP-1 and GIP). By preserving these hormones, Linagliptin stimulates insulin secretion from the pancreas only when blood glucose is elevated — meaning insulin release is glucose-dependent and the risk of hypoglycaemia is very low. It simultaneously suppresses glucagon — the hormone that raises blood sugar — further improving overall glucose control.
Combined Effect: Because both medicines work through entirely separate pathways, their blood sugar lowering effects are genuinely additive — providing stronger glycaemic control than escalating the dose of either medicine individually.
Dosage and Administration
⚠️ Take exactly as prescribed alongside a diabetes-appropriate diet and regular exercise. Never stop without medical advice.
| Indication | Dose | Frequency |
|---|---|---|
| Type 2 diabetes (inadequately controlled on single agent) | 1 tablet (25mg/5mg) | Once daily |
- Take once daily at the same time each day — with or without food
- Swallow whole with a full glass of water
- Maintain adequate fluid intake throughout the day to prevent dehydration from the Empagliflozin component
- Regular HbA1c and kidney function monitoring required during treatment
Active Ingredients
| Ingredient | Strength per Tablet |
|---|---|
| Empagliflozin | 25mg |
| Linagliptin | 5mg |
Who Should NOT Take Xenglu-Lin 25/5mg?
- Type 1 diabetes — not indicated; increases diabetic ketoacidosis risk
- Severe kidney disease (eGFR below 30) — Empagliflozin component becomes ineffective
- Known allergy to Empagliflozin, Linagliptin, or any SGLT2 or DPP-4 inhibitor
- History of pancreatitis — Linagliptin component requires caution
- Pregnancy or breastfeeding — avoid; consult doctor immediately
Consult your doctor before use if you have: moderate kidney disease, recurrent urinary or genital infections, low blood pressure, history of pancreatitis, heart failure, or are taking diuretics or insulin.
Side Effects
Common:
- Genital yeast infections (thrush) — due to increased urinary glucose from Empagliflozin (فنگل انفیکشن)
- Urinary tract infections — increased urinary glucose raises infection risk
- Increased urination — expected effect of urinary glucose excretion
- Nasopharyngitis (runny nose or sore throat) — common DPP-4 inhibitor class effect
Serious — seek medical attention immediately:
- Diabetic ketoacidosis (DKA) — nausea, vomiting, abdominal pain, difficulty breathing — can occur even with near-normal blood sugar (یہ طبی ہنگامی صورتحال ہے)
- Pancreatitis — severe persistent abdominal pain radiating to the back — Linagliptin class risk
- Severe dehydration — dizziness, fainting, markedly reduced urination
- Fournier's gangrene — rare but serious genital area infection requiring emergency care
- Severe allergic reaction — facial swelling, difficulty breathing, widespread rash
- Hypoglycaemia — when combined with insulin or sulphonylureas
Drug Interactions
| Medicine | Interaction |
|---|---|
| Insulin / Sulphonylureas (e.g., Glibenclamide) | Increased hypoglycaemia risk — dose reduction of insulin or sulphonylurea may be needed |
| Diuretics (e.g., Furosemide) | Combined fluid loss increases dehydration and hypotension risk |
| Rifampicin | Reduces Linagliptin blood levels — may reduce effectiveness |
| Strong CYP3A4 inducers | May reduce Linagliptin exposure — inform your doctor |
| Antihypertensives | Additive blood pressure lowering — monitor for hypotension |
Storage Instructions
- Store below 30°C away from moisture and direct sunlight
- Keep in original packaging until use
- Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں)
- Do not use after expiry date on the pack
Frequently Asked Questions (FAQs)
Q: Why is a combination tablet prescribed instead of two separate medicines? Xenglu-Lin combines two complementary mechanisms in one tablet — improving compliance, reducing tablet burden, and providing additive blood sugar lowering that neither medicine achieves as effectively alone.
Q: Can Xenglu-Lin 25/5mg cause low blood sugar on its own? No — both Empagliflozin and Linagliptin have low hypoglycaemia risk when used alone. The risk increases only when combined with insulin or sulphonylurea medicines.
Q: What are the warning signs of pancreatitis I should watch for? Severe persistent pain in the upper abdomen radiating to the back, with nausea or vomiting — stop the medicine immediately and seek emergency medical attention if these symptoms develop.
Q: Should I stop Xenglu-Lin before surgery or during serious illness? Yes — stop at least 3 days before planned surgery and during serious illness to reduce diabetic ketoacidosis risk. Always inform your surgical team and doctor that you are taking this medicine.
⚕️ Medical Disclaimer: This description is for general information only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting or changing this medicine. Report any signs of diabetic ketoacidosis or pancreatitis immediately — these are medical emergencies.
DRAP Registered | Prescription Required (Rx) | Take once daily with adequate fluids — stop before surgery — report abdominal pain or breathing difficulty immediately